



Enzymoics: From amido phosphoribosyltransferase to cholinesterases

Prof. Mohammad Amjad KAMAL
Distinguished Adjunct Professor,
King Fahd Medical Research Center (KFMRC),
King Abdulaziz University,
Jeddah, Saudi Arabia

DATE	: 15 June, Friday (including Q & A session)
TIME	: 0915 – 1030
VENUE	: SCM809
LANGUAGE	: English
FACILITATOR	: Prof. LYU Aiping

Abstract

Enzymes are biological catalysts that speed up the rate of the biochemical reaction without changing itself. Enzymes play important role in catalyzing many biochemical reactions for homeostatic purpose of living organisms while in many diseases/disorders, there are abnormalities in one or more enzymes activities or over expression. Therefore, in the drug discovery research, enzymes have pivotal target for designing of new therapeutic agents either to inhibit or activate specific enzyme. Enzymoics is a novel discipline of such research to discover new medicine for the treatment of various challenging disorders. In this upcoming presentation on 15th June 2018, MA Kamal will present his results related to following three enzymes:

1. Amido phosphoribosyltransferase – For designing and mechanism of action of purine antagonists
2. Acetylcholinesterase - For designing of anti-Alzheimer's therapeutic agents
3. Butyrylcholinesterase - For designing of anti-Alzheimer's therapeutic agents

Speaker

Dr. Mohammad Amjad Kamal is a Distinguished Adjunct Professor at the King Fahd Medical Research Center (KFMRC), King Abdulaziz University, Jeddah, Saudi Arabia, where he was full Professor from March 2011 to March 2013. He is leading a highly productive global collaborative research team based from Novel Global Community Educational Foundation (NGCEF). Dr. Kamal's biochemical research in the field of Alzheimer's disease, Type 2 diabetes and leukemia has culminated in more than 340 publications in internationally respected journals, and 65 abstracts at international conferences.

Dr. Kamal migrated to Australia in 1998 and was awarded a prestigious U2000 Postdoctoral Fellowship in 2000 by the University of Sydney, School of Molecular and Microbial Biosciences. This three years highly competitive award funded his research on the "Inhibition of amido phosphoribosyltransferase by new antifolates: Design and mechanism of action of purine antagonists". Amongst numerous projects, Dr. Kamal also collaborated on the molecular biological research project "Linkage of Alzheimer's disease and Type 2 diabetes" at the University of Technology, Sydney - the commonalities underpinning these two disorders that impact a huge proportion of the world population remain an area of his current scientific focus.

Moreover, he is serving as an EiC/regional/editorial member/guest editor of several reputed scientific journals such as "Seminars in Cancer Biology" etc. on an honorable basis. He is also serving community as a Justice of peace, Dept. of Justice & Attorney General, Australia.

****All are Welcome****